XPH Fact Sheet: State Street SPDR S&P Pharmaceuticals ETF
Share
$64.23
close, Nov 18, 2026
Over the year to Nov 18, 2026, XPH returned +23.8% in total and charged 0.35% a year.
- 1-year total return
- +23.8%
- to Nov 18, 2026
- Expense ratio
- 0.35%
- a year
- Net assets
- $508m
- on Nov 17, 2026
- Net flow, last 5 trading days
- +$20.6m
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
XPH $12,377 +23.8% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+3.2%
3 months−13.2%
Year to date+15.0%
1 year+23.8%
3 years+81.2%
5 years+42.0%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
XERIS BIOPHARMA HOLDINGS INC4.62%
VERADERMICS INC2.67%
ELI LILLY + CO2.67%
PACIRA BIOSCIENCES INC2.64%
VIATRIS INC2.63%
AMNEAL PHARMACEUTICALS INC2.60%
MAZE THERAPEUTICS INC2.52%
ZOETIS INC2.41%
ROYALTY PHARMA PLC CL A2.40%
PERRIGO CO PLC2.33%
XPH top ten by weight, 27.5% of the fund, of its 61 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the S&P Pharmaceuticals Select Industry Index · First traded Jun 22, 2006 · Benchmark Its own holdings, as of Nov 17, 2026